...
首页> 外文期刊>Current allergy and asthma reports. >Patch testing for noncontact dermatitis: The atopy patch test for food and inhalants
【24h】

Patch testing for noncontact dermatitis: The atopy patch test for food and inhalants

机译:非接触性皮炎的斑贴试验:食品和吸入剂的特应性斑贴试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The atopy patch test (APT) is defined as a patch test procedure to assess delayed type hypersensitivity reactions against those protein allergens known to elicit IgE-mediated type I reactions in atopic patients. This patch test procedure uses intact protein allergens instead of haptens in an optimized test setting and with a special reading key. It may be clinically useful especially for atopic dermatitis, as the currently available test procedures either target the wrong reaction type (type I and not type IV) or use the wrong allergens (haptens and not protein allergen). A positive APT reaction correlates with a positive lymphocyte transformation test and allergen-specific Th2 cells in the peripheral blood. As even small changes in the test procedure influence the sensitivity, specificity, and reproducibility of the APT, the European Task Force on Atopic Dermatitis (ETFAD) has developed a standardized APT technique: Intact protein allergens, purified in petrolatum, are applied in 12-mm-diameter Finn chambers mounted on Scanpor tape for 48 h to non-irritated, non-abraded, or tape-stripped skin of the upper back for 48 h; the evaluation of the test reaction is done after 48 and 72 h using the ETFAD reading key, assessing erythema as well as number and distribution pattern of the papules. The APT may reveal type IV sensitization in patients who are negative for the respective type I tests. Limited availability of the expensive test substances and limited reimbursement is among the factors restricting the routine use of the APT.
机译:特应性斑贴试验(APT)被定义为一种贴剂试验程序,用于评估针对已知引起特应性患者中IgE介导的I型反应的那些蛋白质过敏原的迟发型超敏反应。此补丁程序测试过程在优化的测试环境中使用完整的蛋白质过敏原而不是半抗原,并带有特殊的阅读键。它可能在临床上特别是对特应性皮炎有用,因为当前可用的测试程序针对错误的反应类型(I型而不是IV型)或使用了错误的过敏原(半抗原而不是蛋白质过敏原)。 APT反应阳性与外周血中淋巴细胞转化试验和过敏原特异性Th2细胞阳性有关。由于测试程序中即使有很小的变化也会影响APT的敏感性,特异性和可重复性,因此,欧洲特应性皮炎工作组(ETFAD)已开发出一种标准化的APT技术:在凡士林中纯化的完整蛋白过敏原已应用于12-直径直径为Finn的腔室安装在Scanpor胶带上48小时,对上背部的无刺激,无磨损或胶带剥皮的皮肤持续48 h;测试反应的评估是在ETFAD阅读密钥在48和72小时后进行的,评估了红斑以及丘疹的数量和分布方式。对于各自的I型检测阴性的患者,APT可能显示IV型致敏。昂贵的测试物质的有限供应和有限的报销是限制APT常规使用的因素之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号